Condition: Non-small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Colorectal Carcinoma · Sponsor: AstraZeneca
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Gilbert, Arizona, United States | Recruiting |
| Research Site | Duarte, California, United States | Recruiting |
| Research Site | Newport Beach, California, United States | Recruiting |
| Research Site | Santa Monica, California, United States | Recruiting |
| Research Site | Jacksonville, Florida, United States | Recruiting |
| Research Site | Miami, Florida, United States | Withdrawn |
| Research Site | Tampa, Florida, United States | Withdrawn |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | New Brunswick, New Jersey, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Charlotte, North Carolina, United States | Withdrawn |
| Research Site | Winston-Salem, North Carolina, United States | Withdrawn |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05877599